🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — July 30, 2026

The S&P 500 Healthcare sector is showing a clear divergence between top-line growth and bottom-line profitability. While 5 of 6 reporting companies posted revenue growth (Cigna +7%, Regeneron +17%, Bristol Myers +6%, Baxter +5%), margin compression is a dominant theme, with Regeneron's GAAP gross margin falling 500 bps YoY and Bristol Myers' gross margin contracting 120 bps. Forward-looking data reveals a bifurcated outlook: Cigna and Bristol Myers raised full-year guidance, while Baxter's adjusted EPS guidance implies a potential decline. Insider activity is limited but notable, with Edwards Lifesciences' CVP selling a small position. Capital allocation patterns are shifting dramatically—Cigna slashed buybacks by 90% YoY ($250M vs $2.58B), while Regeneron accelerated repurchases to nearly $2B in H1 2026. The sector is investing heavily in R&D and M&A, with Bristol Myers' R&D up 15% and Regeneron's IPR&D expenses surging 1,170%. The overall sentiment is mixed, with strong revenue growth offset by rising costs, margin pressure, and strategic repositioning.

5 high priority 6 medium 11 total filings
· daily

US Earnings Financial Results SEC Filings — July 30, 2026

This digest of 50 pre-analyzed regulatory filings for the period ending June 30, 2026, reveals a market characterized by a stark divergence in performance. While top-line revenue growth is common, with companies like Quanta Services (+41.1% YoY), PBF Energy (+56.2%), and Meta Platforms (+28%) reporting strong gains, profitability is under significant pressure from rising costs, restructuring charges, and increased capital expenditure. A key theme is the 'growth at a cost' dynamic, where aggressive investment in R&D, M&A, and infrastructure is compressing margins and straining cash flows, as seen with Meta, NextDecade, and Life Time Group. The energy sector shows a dramatic turnaround from losses to profits, while the industrial and construction sectors are booming. However, several companies are facing headwinds from currency translation, rising credit losses, and declining core business segments, creating a complex and selective investment landscape. The most critical developments include a massive insider sale at Regeneron, a significant turnaround at PBF Energy, and a sharp profit decline at Pilgrim's Pride, each with distinct market implications.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 30, 2026

The six proxy filings reveal a bifurcated governance landscape: two companies (Zoned Properties and Ocugen) are pursuing transformative but dilutive or conflicted transactions, while others (Lamb Weston, Mexco Energy) focus on routine governance and compensation updates. Period-over-period comparisons are limited as most filings lack explicit financial trends, but capital allocation patterns are clear—Ocugen relies heavily on equity-linked financing (convertible notes requiring share authorization), while Zoned Properties is exiting operations via a management-led buyout. Insider activity is most notable at Zoned Properties, where the buyer group (senior management) creates a severe conflict of interest. Forward-looking data highlights key catalysts: Ocugen's BLA submissions by 2028 and Lamb Weston's new equity plan. The overarching theme is governance risk: two of the six filings involve related-party transactions or dilutive capital raises that require close shareholder scrutiny.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 30, 2026

The IPO pipeline digest for July 30, 2026, reveals a mixed landscape with two new S-1 filings and one routine S-4 filing. Presidio Production Co's S-1 shows strong top-line growth (revenue +15% YoY to $5.0B) and margin expansion (net income +22% YoY to $1.2B), but is tempered by a 7% production decline in its key Oklahoma region, which now contributes 35% of total BOE (down from 40%). Laser Photonics Corp's S-1 highlights significant dilution risk from selling stockholders, including affiliates of placement agent H.C. Wainwright, with no proceeds to the company from share sales. Comcast's S-4 is a routine exchange offer with low materiality. Key period-over-period trends include Presidio's improved operational efficiency (net income growth outpacing revenue growth by 700 bps) and a shift in production mix away from Oklahoma. The most critical development is the potential overhang from Laser Photonics' secondary offering, which could pressure the stock. Portfolio-level patterns show a divergence between capital-intensive energy IPOs (high capex, production risks) and small-cap tech resale filings (dilution risks).

3 high priority 3 total filings
· daily

USA Institutional Investor Activity — July 30, 2026

This digest covers a single 13F-HR filing from Quadrant Private Wealth Management, LLC for the period ended June 30, 2026, filed on July 30, 2026. The filing is a point-in-time holdings snapshot, providing no prior-period comparisons for direct percentage changes. The portfolio shows a balanced mix of mega-cap tech (NVIDIA, Netflix), fixed income ETFs (iShares US Treasury Bond), broad market ETFs (SPDR S&P 500), and thematic exposure (iShares Bitcoin Trust). The lack of prior or aggregate portfolio value data limits trend analysis, but the disclosed positions suggest a growth-with-income tilt and cautious cryptocurrency exposure. The neutral sentiment and moderate materiality score (5/10) reflect the filing's limited forward-looking or comparative value. Key actionable insights derive from the portfolio's composition and implied sector weightings, which can be used to gauge institutional conviction in specific names and asset classes.

1 medium 1 total filings
· daily

US SEC Trading Suspension Halt Orders — July 30, 2026

The regulatory filings from July 24-29, 2026 reveal a concentrated wave of Nasdaq and NYSE listing deficiencies among small-cap and micro-cap companies, signaling heightened regulatory scrutiny and financial fragility in this segment. Four companies—Flux Power Holdings, Curis, Genprex, and Lument Finance Trust—all received or resolved notices related to sub-$1.00 bid prices, a common stress indicator for distressed equities. Genprex's situation is the most acute, having implemented a 1-for-22 reverse stock split and facing an immediate delisting threat under new Nasdaq rules regarding market value of listed securities. Curis narrowly avoided delisting but enters a strict one-year Discretionary Panel Monitor with zero tolerance for future non-compliance. Lument Finance Trust, a mortgage REIT, faces a six-month NYSE cure period, while Flux Power has a 180-day window. The cluster of filings suggests a broader market trend of low-priced stocks struggling to maintain exchange listings, which could trigger forced selling, dilutive reverse splits, or eventual delisting. No period-over-period financial comparisons, insider trading activity, or forward-looking guidance were provided in these filings, limiting quantitative trend analysis but amplifying the binary nature of the risks—compliance or delisting—for each issuer. The materiality is high (8-9/10) for all four, as loss of listing would severely impair liquidity and access to capital for these already vulnerable companies. Investors should view this cluster as a systemic risk signal for the micro-cap ecosystem, where regulatory tightening is accelerating the purge of non-compliant names.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — July 30, 2026

The July 30, 2026, digest of 34 filings reveals a market characterized by strong operational performance in select industrial and consumer names, contrasted with significant leadership transitions and strategic pivots across technology and healthcare. Period-over-period data shows robust revenue growth at MasTec (+23% YoY), Steven Madden (+19.1% YoY), and PTC Therapeutics (+102% YoY), while Forrester Research (-10.3% YoY) and legacy pharma products at PTC declined. The most critical developments include a major CEO succession at Cabot Corp and Stride, Inc., alongside a strategic board appointment at BrainStorm Cell Therapeutics with former FDA leadership. Portfolio-level patterns indicate a strong focus on AI and operational efficiency, with several companies restructuring leadership to accelerate tech-driven growth, while insider activity remains largely absent from these filings, suggesting a focus on strategic board refreshment rather than management conviction signals.

34 high priority 34 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 30, 2026

This digest of 34 SEC filings reveals a significant wave of board and leadership changes across US-listed companies, with a clear emphasis on strategic succession planning and the addition of independent directors with deep operational and financial expertise. Key themes include the appointment of former CEOs and CFOs from major firms (e.g., MGM, Atkore, Affirm) to boards, signaling a focus on operational excellence and capital allocation. Period-over-period data from a subset of companies shows a mixed earnings picture: while MasTec and Steven Madden reported strong revenue growth (23% and 19.1% YoY, respectively), Forrester Research saw a 10.3% revenue decline, and PTC Therapeutics' legacy products continued to erode. Insider activity was limited, but the CEO succession at Stride, Inc. and Cabot Corp. are notable for their orderly transitions. The most critical development is the strategic pivot at BrainStorm Cell Therapeutics, appointing a former FDA official as Executive Chairman to navigate a pivotal Phase 3b trial. Overall, the filings suggest a market focused on refreshing leadership to navigate a complex operating environment, with a mix of growth, transition, and risk.

34 high priority 34 total filings
· daily

USA Insider Trading Pulse — July 30, 2026

Insider trading activity on July 30, 2026, reveals a pronounced bi-directional signal in the US equity markets. A dominant and highly material bearish event is the massive stock sale by Coca-Cola's Chairman James Quincey, who netted ~$34.3M in a pre-planned transaction, marking the largest dollar-value insider sale of the day. In contrast, a defensive and opportunistic buying pattern emerged across several financial and value-oriented firms, including Albertsons, Parke Bancorp, and Vista Credit Strategic Lending Corp, where CEOs and directors added to their positions. A significant cluster of neutral, large-scale dispositions at Open Lending Corp suggests a major corporate event or restructuring, involving multiple C-suite executives and directors. The data indicates a pullback in consumer-facing and tech sectors through insider selling, while select financial and energy pockets exhibit insider confidence. Period-over-period comparisons were largely absent from the filings, limiting trend analysis, but the transactional data provides a clear snapshot of immediate management sentiment.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 30, 2026

The July 30, 2026 M&A digest reveals a bifurcated SPAC market: two newly-formed SPACs (B&R Technology, Lakeshore III) successfully raised capital and amended charters to pursue targets, while two existing SPACs (Keen Vision, DT Cloud Star) face imminent delisting for failing to complete business combinations, signaling a harsh penalty for prolonged deal inactivity. In the operational M&A space, two high-value transactions closed—Etsy’s $1.4B sale of Depop to eBay and Avanos Medical’s $1.27B take-private by AIP—both generating significant cash proceeds for the sellers. AiRWA’s $50M acquisition of Hong Kong Best Life introduces a unique crypto-based payment structure (USDT) and contingent earn-outs, while Iron Horse Acquisition II’s target, Electra Vehicles, secured a marquee client win (Propel Industries) for its battery AI platform. The overall period shows no material revenue or margin trends from these filings, as most are event-driven 8-Ks, but the insider activity and forward-looking data point to a clear catalyst calendar around shareholder votes and SEC reviews for pending deals.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 30, 2026

Overnight filings reveal a market bifurcated between robust operational performance and cautious insider behavior. While 15+ companies reported strong YoY revenue growth (e.g., WESCO +13%, Virtu Financial +19%, Yum China +13%), a significant wave of insider selling—particularly at Natera (6 executives), CoreWeave, and Roivant Sciences—signals potential valuation concerns or profit-taking at elevated levels. The most material corporate action is the $8.5B Arcosa acquisition by CRH, reinforcing a consolidation trend in building materials. Mixed sentiment dominates, with many companies showing top-line strength but margin compression (e.g., Solstice Advanced Materials, Magnum Ice Cream) or declining cash flows (CRH, WESCO). The IPO pipeline is active with Braveheart Bio filing for a $319M offering. Key themes include data center/AI infrastructure demand (WESCO, AITX), margin discipline challenges, and a divergence between reported earnings and underlying cash generation.

28 high priority 22 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 29, 2026

This July 29, 2026 digest covers three FDA approvals, all classified as 'Other' (FALLBACK type), with zero NMEs, zero biosimilars, and zero label expansions. The period lacks a dominant therapeutic area theme, as the approvals span neurology (DIAZEPAM), endocrinology (INSULIN ASPART-FSAN), and neurology (TOPIRAMATE). The highest-conviction signal is the bullish NME approval of INSULIN ASPART-FSAN (GARZULYS) by EMERGE BIOSCIENCE PTE. LTD., representing a potential new entrant in the insulin market, though commercial details remain undisclosed. Key risks include the lack of clarity on pricing, exclusivity, and market positioning for all three drugs, limiting actionable investment conclusions. The overall signal mix is 1 bullish, 0 bearish, and 2 neutral, reflecting a low-impact period for biotech small-cap investors.

3 total filings
· daily

New Drug Approvals (Original) — July 29, 2026

During the single-day period of July 29, 2026, the FDA approved 3 non-NME, non-biosimilar, non-label-expansion drugs—classified as 'Other' (likely generic or follow-on approvals). The mix featured zero new molecular entities, zero biosimilars, and zero label expansions, indicating a low-catalyst session for institutional investors. The highest-conviction signal was EMERGE BIOSCIENCE PTE. LTD.'s approval of INSULIN ASPART-FSAN (branded GARZULYS), classified as an NME approval but flagged as a 'Fallback' type, suggesting potential classification ambiguity; this represents a potential entry into the $20B+ insulin market. The remaining approvals—DIAZEPAM by LUPIN and TOPIRAMATE by BIOCON PHARMA—are low-materiality generic entries generating neutral signals. Key watch item: clarify whether EMERGE's INSULIN ASPART-FSAN holds NCE exclusivity or faces immediate competition given its Fallback designation.

3 total filings
· daily

Federal Construction & Infrastructure Contracts — July 29, 2026

The digest covers a single $97.4 million civilian contract awarded to Tutor Perini Corporation by the Department of Homeland Security (Coast Guard) for residential construction in Kodiak, Alaska. This is a 100% civilian infrastructure award with no defense exposure, reflecting stable but non-growth-oriented federal housing spending. The highest-conviction signal is neutral: the fixed-price design-build structure in a remote location introduces execution risk, while the full-and-open competition suggests no durable competitive moat. Key risk is the high pricing risk from remote logistics and the fact that only $3 million has been outlayed, leaving $94 million in future revenue subject to performance milestones.

1 total filings
· daily

Defense Manufacturing Contracts — July 29, 2026

This digest covers a single $53.2 million civilian contract awarded to Bell Textron Inc. by the Department of the Interior (DoI) for U.S. Park Police helicopters. The award is non-competitive and firm-fixed-price, representing a one-time procurement with no options, which limits revenue visibility beyond the 2.5-year performance period. The highest-conviction signal is neutral, as the sole-source nature suggests a competitive moat but also introduces execution risk on fixed-price terms with no cost-sharing. Key risk includes potential margin compression from fixed-price execution on specialized rotary-wing aircraft, with no defense exposure to offset civilian budget volatility.

1 total filings
· daily

DHS Homeland Security Contracts — July 29, 2026

The two DHS contracts awarded on July 29, 2026, total $160.8 million, with zero defense-related spending, underscoring a civilian homeland security focus. The dominant theme is infrastructure modernization: Tutor Perini Corporation’s $97.4 million Coast Guard housing project in Kodiak, AK, and Advanced Technology Systems Company’s (ATSC) $63.5 million border surveillance award for CBP. The highest-conviction signal is ATSC’s small-business win in surveillance technology, which aligns with DHS border security priorities and offers upside from $114.7 million in options. Key risks include Tutor Perini’s fixed-price execution in a remote Arctic location and ATSC’s zero outlayed amount to date, delaying revenue recognition. Investors should monitor Tutor Perini’s quarterly segment margins and ATSC’s option exercise announcements for near-term catalysts.

2 total filings
· daily

New Federal Contractors — July 29, 2026

This digest of 10 new federal contractor awards, totaling $731.6 million, reveals a civilian-agency dominated landscape with zero defense-related contracts. The dominant theme is a surge in civilian IT and professional services spending, led by the General Services Administration (GSA) which awarded four of the ten contracts. The highest-conviction signal is a bullish outlook for KADIAK LLC ($88.6M) and HII Mission Technologies Corp ($70.5M), both securing multi-year awards with strong government commitment. A key risk is the high execution risk on fixed-price contracts in remote locations, notably Tutor Perini Corporation's $97.4M Coast Guard housing project in Kodiak, AK, and Bell Textron's $53.2M sole-source helicopter contract, where cost overruns could squeeze margins.

10 total filings
· daily

Significant Contract Modifications ($10M+) — July 29, 2026

The 11 contracts totaling $732.5 million are overwhelmingly civilian (10 of 11), with only one defense-related award (Sigma Defense Systems' $56.8M Navy maritime surveillance support). The dominant theme is stable civilian agency spending on IT services, construction, and professional support, with the General Services Administration (GSA) as the most active agency (4 contracts, $289.9M). The highest-conviction signal is KADIAK LLC's $88.6M obligated DOI contract, which benefits from a structural set-aside advantage for Alaskan Native Corporations. Key risks include zero outlayed amounts on several large awards (KARSUN Solutions' $98.4M, ATSC's $63.5M) indicating uncertain near-term revenue recognition, and execution risk on fixed-price construction in remote locations (Tutor Perini's $97.4M Kodiak, AK project).

11 total filings